Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Ca... ( ANN ARBOR Mich. Jan. 12 /- Rubicon Ge...)

Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests

Date:1/12/2009

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and Option Agreement for development and commercialization of Rubicon MethylPlex(TM) methylation detection technology for the diagnosis and prognosis of cancer.

Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and colon cancer for screening and non-screening indications. Abbott also obtains a non-exclusive license for non-screening applications with other diseases and options to colon cancer biomarkers developed in collaboration with Rubicon.

"This license is a significant validation of the MethylPlex technology as an effective, simple, automatable method for detecting cancer using DNA methylation in patient plasma," said James Koziarz, Acting President and CEO of Rubicon. Mr. Koziarz went on to say, "The collaboration between Rubicon and Abbott has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays. We look forward to continuing our joint efforts under our collaboration and developing leading edge products."

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performance of analytical platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensi
'/>"/>

SOURCE Rubicon Genomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers

Post Your Comments:

(Date:11/29/2009)... The Academy of General Dentistry (AGD) ...CA, received the Mastership Award during the AGD,s...ers, commitment to excellence in dental education....ours of approved continuing dental education in th... dedicated to hands-on skills and techniques. , ...

(Date:11/29/2009)...one get blamed for something leads to more self-de... SUNDAY, Nov. 29 (HealthDay News) -- The blame gam...hen the target is innocent. , Researchers found...or a problem, even if it,s an unfair accusation, t...s, too. , "When we see others protecting their...

(Date:11/29/2009)... Traditional healthcare,s uncertain futu...dable alternative care. Affordable Acupuncture Sco... (PRWEB) November 29, 2009 -- Affordable Acupunc...r (2009) and has been met with enthusiasm and grat... can be attributed to two things, need and cost. ...

(Date:11/28/2009)...e variation believed to affect circadian rhythm,... -- New research suggests that an internal body cl...e development of bipolar disorder in children. ,... genetic makeup of 152 children with bipolar disor...od swings, and 140 children without the disorder. ...

(Date:11/27/2009)... Biotech firm Replikins Ltd. today issue...s genomic data. It shows that the lethality of th...) during the virus,s current outbreak in the sprin... of 2.0 (s.d. 0.1). The H1N1 infectivity count, ho... Boston (PRWEB) November 27, 2009 -- Biotech fir...

Breaking Medicine News(10 mins):Health News:Orange County Dentist Honored by The Academy of General Dentistry 2 Health News:When Accusations Start to Fly, They Multiply 2 Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2 Health News:Bipolar Disorder May Be Tied to Body Clock 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5

[1] Orange County Dentist Honored by The Academy of General Dentistry [1] When Accusations Start to Fly, They Multiply [0] Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities [0] Bipolar Disorder May Be Tied to Body Clock [0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased

...venue and Earnings Guidance for 2008, - Total Reve...268.0mm for Fourth Qua...p 16% to $1.59 for Full Year, (GAAP EPS down 11% t...thening Across Segments, - Reconfirming 2008 Reven...

..., Calif., Feb. 28 Cardiva Medical, Inc., a,privat...he Boomerang,Catalyst(TM) System announces that it...lyst II System on February 29 at 9:20am at the Med...n in Las Vegas, NV., The Boomerang Catalyst II Sy...

...he most effective treatment for lowering cholester...be safe in large clinical trials. Although side ef...especially musculoskeletal complications, have bee... of Arthritis Care & Research ( http://www.intersc...

...r 2007 And Full Year 2007 Highlights, - Revenue ... from the, fourth quarter of 2006. Revenue for the...rease from $1.3 billion for full year 2006., - Ave...lity Operating Income for the fourth quarter grew ...

...breast cancers for three receptors could help doct...rain metastases. A study published in the open acc...ents with tumours that are negative for estrogen r...brain metastases. Survival is also correlated to t...

...eb. 27 Today, the U.S. House,Foreign Affairs Comm...PEPFAR, the U.S. Global Leadership Against HIV/AID...08., Tony Perkins, President of Family Research C...ontained in earlier drafts. Previous,drafts would ...

inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the 'Investment in Innovation (In3) West' Conference on February 29, 2008 in Las Vegas, NV Tendon complications, though rare, linked to statins Brookdale Announces Fourth Quarter and Full Year 2007 Results Breast cancer subtypes linked to survival from secondary brain tumors Bipartisanship Trumps Liberal Agenda in PEPFAR Reauthorization

(Date:11/29/2009)... , CHICAGO, Nov. 29 Royal Ph... its response to an industry need by showing its p...tion at this year,s 95th annual meeting of the Rad...go. New this year from Philips are several advanc... managing dose radiation and streamlining workflow...

(Date:11/29/2009)..., CHICAGO, Nov. 29 FUJIFILM Med...R D-EVO*, its revolutionary flat panel DR cassette...a (RSNA) Annual Meeting. Ideal for any clinical e...ology to provide clinicians with Fujifilm,s tradem..., D-EVO is a smart way for users to transition ...

(Date:11/29/2009)..., CHICAGO, Nov. 29 Stimulated b...eadership Fujifilm Medical Systems USA announced t... (RSNA) annual meeting, the formation of its Medi...orks Systems, this new group will integrate all fu...offering and creates a platform for future growth....

[0] Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients [0] FUJIFILM's DR Cassette Makes World Debut [0] FUJIFILM Establishes Medical Informatics Organization

...IELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - C...r Astellas Pharma US, Inc. ("Astellas") today,anno...3 clinical,study, called ACT 2. The trial evaluate...lation of vernakalant hydrochloride,("vernakalant ...,atrial fibrillation or atrial flutter between 24 ...

...all/ -- ZymoGenetics,Inc. today announced that in...ical trial with atacicept in B-cell chronic,lympho...Clinical,Oncology (ASCO) 2007 annual meeting. The ...r doses than had been tested in previous,studies. ...biologically,active at all dose levels in this stu...

Other Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2 Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3 Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4 Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5 Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6 ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2 ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3

Cardiome And Astellas Announce Positive Results From ACT 2 Trial ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...

Medicine Products:

Human Immunodeficiency Virus 2 Antibody Confirmation by IFA Human Immunodeficiency Virus 1,2 Combined Antibodies with Reflex to HIV-1 Confirmation by Western Blot Human Immunodeficiency Virus 1 RNA Quantitative PCR with Reflex to Ultrasensitive RNA Quantitative PCR Human Immunodeficiency Virus 1 Antibody, Confirmation

Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Ca...( ANN ARBOR Mich. Jan. 12 /- Rubicon Ge...),Health